

News

[Investor Alerts](#) 

All Years All Categories

Search

[Advanced Search](#)



24 Apr 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...

 [Photos \(1\)](#)  [Documents \(2\)](#)



14 Apr 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...

 [Photos \(1\)](#)  [Video \(1\)](#)

10 Apr 2023

This is a test from PR Newswire

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR...

08 Apr 2023

This is a test from Cision

THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG'S TAIL This is a test from Cision The Quick Brown Fox Jumps Over The Lazy Dog's Tail. The Quick Brown Fox Jumps Over The Lazy Dog's Tail. The Quick...

26 Mar 2023

Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer

Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive Phase III...

Show 5 per page



<https://aall.investorroom.com/news?l=5&o=225>